Trial Outcomes & Findings for Weighted Blankets With Infants With NAS (NCT NCT03113656)

NCT ID: NCT03113656

Last Updated: 2019-09-19

Results Overview

Finnegan scale measures signs of neonatal drug withdrawal syndrome. It provides a summative score obtained from the assessment of 21 items related to neonatal withdrawal. The total score ranges from 0 to 43 with a higher score indicating more severe symptoms. Values above 8 have been described as being indicative of neonatal abstinence syndrome.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

16 participants

Primary outcome timeframe

baseline and 30 minutes

Results posted on

2019-09-19

Participant Flow

Participant milestones

Participant milestones
Measure
Weighted Blanket First
This group will receive the Weighted Blanket first and then the Non-weighted blanket Weighted Blanket: Weighted blanket placed on infant for 30 minutes Non-Weighted Blanket: Non-Weighted blanket placed on infant for 30 minutes
Non-weighted Blanket First
This group will receive the Non-weighted Blanket first and then the Weighted blanket Weighted Blanket: Weighted blanket placed on infant for 30 minutes Non-Weighted Blanket: Non-Weighted blanket placed on infant for 30 minutes
Overall Study
STARTED
9
7
Overall Study
COMPLETED
9
7
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Weighted Blanket First
n=9 Participants
This group will receive the Weighted Blanket first and then the Non-weighted blanket Weighted Blanket: Weighted blanket placed on infant for 30 minutes Non-Weighted Blanket: Non-Weighted blanket placed on infant for 30 minutes
Non-weighted Blanket First
n=7 Participants
This group will receive the Non-weighted Blanket first and then the Weighted blanket Weighted Blanket: Weighted blanket placed on infant for 30 minutes Non-Weighted Blanket: Non-Weighted blanket placed on infant for 30 minutes
Total
n=16 Participants
Total of all reporting groups
Age, Continuous
6.89 days
STANDARD_DEVIATION 8.24 • n=9 Participants
4.00 days
STANDARD_DEVIATION 3.06 • n=7 Participants
5.63 days
STANDARD_DEVIATION 6.49 • n=16 Participants
Sex: Female, Male
Female
4 Participants
n=9 Participants
5 Participants
n=7 Participants
9 Participants
n=16 Participants
Sex: Female, Male
Male
5 Participants
n=9 Participants
2 Participants
n=7 Participants
7 Participants
n=16 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
9 participants
n=9 Participants
7 participants
n=7 Participants
16 participants
n=16 Participants

PRIMARY outcome

Timeframe: baseline and 30 minutes

Population: Reporting Arms/Groups "per intervention"

Finnegan scale measures signs of neonatal drug withdrawal syndrome. It provides a summative score obtained from the assessment of 21 items related to neonatal withdrawal. The total score ranges from 0 to 43 with a higher score indicating more severe symptoms. Values above 8 have been described as being indicative of neonatal abstinence syndrome.

Outcome measures

Outcome measures
Measure
Intervention
n=16 Participants
Weighted Blanket: Weighted blanket placed on infant for 30 minutes
Control
n=16 Participants
Non-Weighted Blanket: Non-Weighted blanket placed on infant for 30 minutes
Change in Finnegan Score
-1.5167 score on a scale
Standard Deviation 2.251
-0.2549 score on a scale
Standard Deviation 1.787

Adverse Events

Intervention

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Nurse Researcher

TriHealth

Phone: 513-569-6191

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place